http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20090423:RnsW0214R
                                                                                                                       .
RNS Number : 0214R

Alizyme PLC

23 April 2009


  For immediate release   23 April 2009


ALIZYME PLC

BOARD CHANGES

Cambridge UK, 23 April 2009: Alizyme plc (LSE:AZM) announces that Sir Brian
Richards has informed the Board that he intends to step down as Chairman and
retire as a Director of Alizyme plc at the conclusion of the forthcoming Annual
General Meeting, to be held on 24 July 2009. Sir Brian has been Chairman of
Alizyme since its formation.

Mr Alan Goodman joins the Board as a Non-Executive Director with immediate
effect and it is intended that he will assume the role of Chairman at the
conclusion of the forthcoming Annual General Meeting.

Mr Goodman, aged 58, has founded or co-founded many biotechnology and healthcare
companies over the last 25 years, including Agricultural Genetics Company,
Medeva plc, Chiroscience Group plc, Acambis plc, Oxford BioMedica plc, CeNeS
Pharmaceuticals plc, Core Group plc and Amura Limited. He was Chief Executive of
Acambis plc, non-executive Chairman of Oxford BioMedica plc and is currently a
member of the Supervisory Board of Paion AG and Chief Executive of Avlar
BioVentures Limited and a director of a number of private companies.

There are no other disclosures relating to Mr Goodman under Listing Rule LR
9.6.13.

Tim McCarthy (Chief Executive Officer) commented:

"Sir Brian has provided invaluable guidance and advice as Chairman of Alizyme
since its formation, for which I and the Company are immensely grateful. I want
to thank him for his unstinting efforts and wise counsel over many years and
wish him well for the future. I welcome Alan's appointment as a Non-Executive
Director and believe his succession as Chairman will bring a wealth of
experience to the Board and is an important step for Alizyme in pursuing its
strategy to become a profitable, self-sustaining biopharmaceutical product
development company."

For further information, please contact:


  ALIZYME PLC                               Tel: + 44 (0) 1223 896000
  Tim McCarthy, Chief Executive Officer

  BUCHANAN COMMUNICATIONS                   Tel: + 44 (0) 20 7466 5000 Tel: + 44 (0) 7721 413496
  Lisa Baderoon
  Rebecca Skye Dietrich


Further information on Alizyme can be found on the Company's website:
www.alizyme.com


This information is provided by RNS

The company news service from the London Stock Exchange

  END

BOAIFFSISIIFFIA